Prostate Cancer - Results from #1880

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer. November 3, 2023

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer. November 3, 2023

Androgen blockade primes NLRP3 in macrophages to induce tumor phagocytosis. November 3, 2023

Clinically relevant humanized mouse models of metastatic prostate cancer to evaluate cancer therapies. November 3, 2023

Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer. November 3, 2023

5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapy. November 3, 2023

Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-Variant Prostate Cancer. November 3, 2023

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine. November 3, 2023

Loss of Feedback Regulation between FAM3B and Androgen Receptor Driving Prostate Cancer Progression. November 3, 2023

MRI characteristics and oncological follow-up of patients with ISUP grade group 4 or 5 prostate cancer. November 2, 2023

Effect of a Home-based Walking Intervention on Cardiopulmonary Fitness and Quality of Life Among Men with Prostate Cancer on Active Surveillance: The Active Surveillance Exercise Randomized Controlled Trial. November 2, 2023

Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. November 2, 2023

Prostate Cancer Disparities in Metastatic and Treatment Status for Hispanic Americans Based on Country of Origin Compared to Non-Hispanic Whites Using the National Cancer Database. November 2, 2023

Outcomes of salvage robot-assisted radical prostatectomy in patients who had primary focal versus whole-gland ablation: a multicentric study. November 2, 2023

CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer. November 1, 2023

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. November 1, 2023

Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors. November 1, 2023

Racial disparity in the utilization of immunotherapy for advanced prostate cancer. November 1, 2023

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer. November 1, 2023

Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial. October 31, 2023

Page 95 of 1436